Die Grafik zeigt die prognostizierten Quartalsgewinne (Bereinigter Gewinn pro Aktie, EPS) und die tatsächlich erzielten Gewinne (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Umsatz (USD)
Schätzung
Umsatz
Die Grafik zeigt die prognostizierten Quartalsumsätze und die tatsächlich erzielten Umsätze (grün: Analystenschätzungen übertroffen, rot: Analystenschätzungen verfehlt) für den ausgewählten Zeitraum.
Güte der Analystenschätzungen – EPS (aktueller Zeitraum)
Quartal / Datum
EPS (USD)
Schätzung (USD)
Abweichung
Quartal / Datum
Umsatz (Mrd USD)
Schätzung (Mrd USD)
Abweichung
Revisionen der Gewinnschätzungen
EPS-Schätzungen für die Geschäftsjahre
2026, 2027, 2028.
MILAN--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings is OSD Express, a defined solution designed to increase predictability.
Thermo Fisher Scientific, the laboratory-equipment and life-sciences services company (TMO), joined JPMorgan's (JPM) October growth selections, with shares up a
Park National Corp OH grew its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 1,067.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,329 shares of the medical research company's stock after purchasing an additional 5,787
Rockland Trust Co. decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 46.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 34,723 shares of the medical research company's stock after selling 29,916 shares during the period. Rockland Trust Co.'s holdings in
Ferguson Wellman Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 11.9% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,904 shares of the medical research company's stock after buying an additional
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its strategic collaboration with Precision Health Research, Singapore (PRECISE) and Nanyang Technological University, Singapore (NTU Singapore) has led to the discovery of more than 2,500 previously unreported genetic-protein associations. By combining Thermo Fisher's complementary proteomics technologies with PRECISE-SG100K's large-scale health and genomic data, researchers.
MassMutual Private Wealth and Trust FSB reduced its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 2.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 50,766 shares of the medical research company's stock after selling 1,348 shares
You can't buy Neuralink stock yet, but its supply chain is already public. Here are the brain-computer interface stocks to watch before the Neuralink IPO.
Portfolios
0
Zum Anlegen oder Bearbeiten von Portfolios müssen Sie sich anmelden oder einen Account erstellen.
Aktuelle Aktie in ein Portfolio speichern oder neues Portfolio anlegen: